Drug profile · INN
axatilimab-csfr
NIKTIMVO
axatilimab-csfr (NIKTIMVO) is a macrophage colony stimulating factor receptor inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — axatilimab-csfr
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
axatilimab-csfr (NIKTIMVO) is a macrophage colony stimulating factor receptor inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Macrophage colony stimulating factor receptor inhibitor
Primary target: Macrophage colony-stimulating factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Congress & event coverage
- PresentationEULAR 2026
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is axatilimab-csfr?
axatilimab-csfr (NIKTIMVO) is a macrophage colony stimulating factor receptor inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for axatilimab-csfr?
NIKTIMVO is a marketed brand name for axatilimab-csfr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of axatilimab-csfr?
axatilimab-csfr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.